View press release distributed by EIN Press Access:
https://www.einpresswire.com/article/847032843/biomed-industries-to-present-phase-2-results-on-na-931-an-oral-alternative-to-injectables-for-obesity-easd-2025-austria
SAN JOSE, CA, UNITED STATES, September 8, 2025 -- Biomed Industries, Inc. (“Biomed”) today announced that Dr. Lloyd L. Tran, the company’s Chief Executive Officer, will present results from its Phase 2 clinical trial of NA-931, a first-in-class oral quadruple receptor agonist for the treatment of obesity, at the EASD 2025 (European Association for the Study of Diabetes), taking place on September 15-19, 2025 in Vienna, Austria.
Dr. Tran’s oral presentation, scheduled September 17, is titled: “Phase 2 Clinical Trials of NA-931, an Oral Novel Quadruple IGF-1, GLP-1, GIP, and Glucagon Receptor Agonist, Reduces Body Weight Without Muscle Loss.”
NA-931 :
NA 931, also known as Bioglutide™, is a small molecule medicine designed to activate four metabolic hormone receptors—insulin like growth factor 1 (IGF 1), glucagon like peptide 1 (GLP 1), glucose dependent insulinotropic polypeptide (GIP), and glucagon—via oral administration. NA 931 is being developed as a potential oral alternative to injectable weight loss therapies.
Phase 2 Results of NA-931 :
The Phase 2 study was a randomized, double-blind, placebo-controlled, parallel-arm clinical trial evaluating the safety, tolerability, efficacy, pharmacodynamics, and pharmacokinetics of NA-931 in adults with obesity (BMI ≥30 kg/m²) or who are overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity.
The Phase 2 trial confirmed the robust efficacy and favorable safety profile seen in Phase 1. NA-931 achieved weight loss outcomes on par with leading approved and late-stage injectable therapies, while showing significantly fewer and milder side effects.
Additional Presentation: Association of obesity and Alzheimer’s Disease
In addition to the oral presentation, Biomed will present a scientific poster titled: “Association Between Alzheimer’s Disease (AD) and Obesity: Clinical Trial Results of NA-831 for AD and NA-931 for Obesity.”
Biomed’s research team is among the first to identify the possible mechanistic link between obesity and Alzheimer’s disease, driven by its dual development programs in NA-831 (for AD) and NA-931 (for obesity).
The 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) is one of the largest conferences in the diabetes field worldwide. The EASD 2025 program features groundbreaking basic research, cutting-edge clinical trial results and in-depth expert presentations from around the world, with key discussions and debates that will shape the future of diabetes research and care.
“We are honored and excited to present our promising Phase 2 data for NA-931 at this prestigious conference,” said Dr. Lloyd Tran, CEO of Biomed Industries. “We believe the future of obesity treatment lies in safe, effective, and accessible oral therapies. NA-931 is a first-in-class innovation that provides an oral alternative to injectable drugs. We look forward to sharing our data with the global scientific community.”
THE URGENT NEED FOR EFFECTIVE AND SAFE OBESITY TREATMENT
Obesity remains a critical global health challenge, contributing to comorbidities such as type 2 diabetes, cardiovascular disease, liver disease, and chronic kidney disease. More than 650 million people worldwide are affected by obesity, and this figure is expected to surpass 50% of the global population by 2035. Current treatments often target limited aspects of the condition, underscoring the need for more comprehensive therapies like NA-931.
ABOUT NA-931 :
NA-931 is the first-in-class, orally active, small-molecule quadruple receptor agonist that simultaneously targets IGF-1, GLP-1, GIP, and glucagon receptors. This multi-pathway approach restores metabolic balance and induces clinically meaningful weight loss—without muscle loss or severe side effects. In Phase 1 trials, NA-931 demonstrated potential benefits for both weight reduction and glycemic control in individuals with type 2 diabetes.
Biomed recently completed a Phase 2, randomized, double-blind, placebo-controlled, 13-week study in patients with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. Topline results will be announced on June 20, 2025, at ADA 2025. (ClinicalTrials.gov ID NCT06564753)
ABOUT BIOMED INDUSTRIES, INC.
Biomed Industries, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing transformative therapies for chronic and complex diseases. The company’s investigational pipeline targets a wide range of unmet medical needs, including:
- Alzheimer’s disease
- Major depressive disorder (MDD)
- Obesity and diabetes
- Metabolic dysfunction-associated steatohepatitis (MASH)
- Stroke and alcohol use disorder
- Rare diseases, including Rett Syndrome and Fragile X
For further information, please visit Biomed Industries' official website: https://www.biomedind.com
CONTACT
Michael Willis
Biomed Industries, Inc.
San Jose, CA 95131 USA
Tel. 800-824-5135
Email: media@biomedind.com
https://www.biomedind.com
For more news, please visit our News page.
For further information about Biomed Industries, Inc., please contact us.